Favourable data on in vitro activity of cefuroxime have been published by various authors (Eykyn et al. 1976 , Norrb.y et al. 1976 , O'Callaghan et al. 1976 . In protection studies with mice, rats and rabbits it was also very effective (Ryan et al. 1976) . In this study its renal tolerance and efficacy on Escherichia coli pyelonephritis were evaluated in rats.
Materials and Methods
The methods both for nephrotoxicity testing and for chemotherapy of experimental chronic E. coli pyelonephritis have been described previously (Commichau et al. 1976 , Sack 1976 . Female albino Wistar rats, average weight 200 g, were used in both models.
Nephrotoxicity Testing
After a pretest period of 2 days for estimation of the basic parameters, cefuroxime was given i.m. in 9 single doses on 5 successive days with 12 h intervals. Groups of 10 rats were treated with different doses (1000, 2000, 3000 and 5000 mg/kg/ day). After 6 ml of water had been given to the animals by oral tube they were placed singly in metabolic cages overnight. Urine was collected over a 12 h period and displayed against tap water. The activity of urinary malic dehydrogenase (MDH) was estimated as mU/12 h (1000 mU=1 Unit=16.67 nka) and the tubular cells were counted in a Fuchs-Rosenthal chamber. Twelve h after the last application, 5 animals from each group were killed for histological investigation of the kidneys and estimation of blood urea.
The 5 remaining rats of each group were killed on the twelfth day, after 3 more urinalyses.
Efficacy Testing
For evaluation of in vivo activity, cefuroxime was tested in 4 experiments and compared to 5 other cephalosporins (cephalothin, cephapirin, cefazolin, cephacetrile and cefamandole). Groups of 25 rats were treated with cstradiol undecylate (0.5 mg/kg) weekly during the whole test period. Infection was initiated by transurethral instillation of about 5 x 108 viable organisms (E. coli, strain 0 25:19:12), suspended in 1 ml of saline, into the bladder. Ten days after a second infection, the cephalosporins were administered twice daily (2 x 150 mg/kg) over a period of 1 week. Results of therapy were assessed by quantitative culture of the homogenized kidneys 3 days after the last dose.
Besides this pyelonephritis model which requires cestradiol treatment to establish a chronic course, a variant of the model was introduced in the study using E. coli 0 2:1:4, which persists without cestrogen.
Minimal inhibitory concentrations (MIC) were determined by the tube dilution method using Mueller-Hinton broth (Oxoid, CM 405) according to a standard technique (Ericsson & Sherris 1971) . Details of pharmacokinetic evaluation in rats have been published by Marre & Freiesleben (1977) . Fig 1 demonstrates the course of excretion of tubular cells estimated day by day during treatment and at 2-day intervals thereafter. It remained within the normal range for the whole test period up to the 3000 mg dose. The normal range is shaded in Fig 1 indicating the median value of the pretest control period and the upper tolerance limit. Only after 5000 mg/kg/day did a pathological excretion occur. It gradually returned to normal during the post-treatment observation period.
RESULTS

Renal Tolerance
The same result was obtained by evaluation of the urinary excretion of malic dehydrogenase ( only in the series treated with 5000 mg/kg/day.
Histologically, however, no tubular necroses nor pathological changes of the glomerular capillaries were to be found. Proteinuria (estimated by Stix method) did not occur at that dose and blood urea was never elevated. Thus, the tubulotoxic threshold dose, i.e. the lowest dose for which pathologic findings were demonstrable, was 5000 mg/kg/day (Table 1) .
Therapeutic Efficacy
In the first trial cephalothin, cephapirin and cefuroxime were compared to an untreated con-trol group (Fig 3) . The mean log number of bacteria/g kidney was 2.9 for the control and 0.6 for the cefuroxime treated group. The difference was statistically significant, whereas cephalothin had no significant effect in this experiment and cephapirin had intermediate efficacy. In the next trial (Fig 4) cefuroxime was compared to cephacetrile. The mean log number of organisms, 3.9 for cephacetrile, was only slightly reduced against the untreated control, the significance of the difference being 0.05-0.1 by the U-Test. Cefuroxime exerted a significantly better result.
The next trial ( Fig 5) brought about extraordinarily good results for cefazolin as well as for cefuroxime using the E. coli strain 0 2:1:4 without application of estradiol. Again using the 0 25model ( Fig 6) cefuroxime revealed superior efficacy, the mean log number of organisms being significantly lower than after therapy with cefamandole or cefazolin.
Additional investigations on in vitro activity against the applied E. coli strains demonstrated that they were cephalothin sensitive but that certain differences existed between the cephalosporins (Table 2 ). Substantial differences in pharmacokinetics were also found in rats by determination of serum levels, which were used cephalotin 2 x150 mg/kgAd Table 2 ).
Discussion
The tubulotoxic threshold doses for rats are higher than the human dosages for all cephalosporins. Nevertheless, the differences of the threshold doses (e.g. 500 and 3000 mg/kg/day for cephaloridine and cephalothin respectively) correspond to the clinical experience of nephrotoxicity or renal tolerance of the drugs. The very high tubulotoxic threshold dose of 5000 mg/kg/day for cefuroxime suggests an even better renal tolerance than cephalothin, cephacetrile or cefamandole.
The results of experimental chemotherapy in rats were similarly favourable for cefuroxime. Only in 1 trial was the comparison drug cefazolin as effective as cefuroxime. In this experiment, however, the pyelonephritis model with the E. coli 0 2 strain was used which, as a rule, gives better therapeutic results. The maximum effects achieved in this case did not allow differentiation ofefficacy. In the next trial with the E. coli 0 25 strain and cestrogen treatment, which impairs host defence mechanisms, cefuroxime proved to be superior to cefazolin. Four other cephalosporins were also less effective than it.
After administration of the same single doses as were given for therapy, different serum concentrations were found in rats, a finding which becomes evident by calculation of the areas under the curves. The different pharmacokinetic behaviour is to a certain degree consistent with the findings of in vivo efficacy. An additional explanation may be derived from different MICs of the drugs for the test organisms. The lack of correlation for cefazolin may probably be accounted for by its high rate of protein binding.
In conclusion, comparative evaluation of cefuroxime for renal tolerance and in vivo efficacy in rats has led to favourable results, which support the impression that cefuroxime is one of the most promising new cephalosporins.
Summary
The renal tolerance of cefuroxime was investigated in female albino Wistar rats. The drug was administered i.m. in different dosages (1000, 2000, 3000 and 5000 mg/kg/day, dosage intervals 12 h) over a period of 5 days. The excretion of tubular cells and urinary malic dehydrogenase was assessed before, during and after administration of the drug. In addition, the concentration of serum urea was analysed and the renal histology was examined. For cefuroxime, a tubulotoxic threshold dose of 5000 mg/kg/day was found. In comparison to other cephalosporins, cefuroxime belongs to those antibiotics for which a high degree of renal tolerance was demonstrated.
The therapeutic efficacy of cefuroxime and other cephalosporins (cephalothin, cephapirin, cefazolin, cephacetrile and cefamandole) was tested using the experimental model of cestradiolinduced Escherichia coli pyelonephritis (strain 0 25:19:12) and a variation of this model without hormonal facilitation (strain 0 2:4:1) in rats. In all trials the mean log number of bacteria/g kidney tissue was significantly reduced compared to the untreated control groups. Applying the same dosage with all the cephalosporins (2 x 150 mg/ kg/day over a period of 7 days), cefuroxime treatment resulted in a better effect than the other derivatives.
